Showing results (101-110 of 154) with videos related to
Sort By:
Pageof 16
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.Cancer|July 26, 2017
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patientsPreetesh Jain, Hagop M Kantarjian, Ahmad Ghorab, et al.Nature Communications|March 19, 2025
Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibitionXiangguo Shi, Minhua Li, Zian Liu, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Haematologica|July 2, 2026
Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemiaGhayas C Issa, Richard A Larson, Timothy P Hughes, et al.The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemiaDaniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.Pageof 16